Najam Syed, MD
Family Practice · Taylor, MINPI 1588688717
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,346, 2.2 times the $598 reported in 2019. Among family practice clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Pfizer$768
- Novo Nordisk$576
- GSK$565
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$307
- plus $2K from 33 others
What the payments were for
- Food & beverage$7,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $1,377 |
| AstraZeneca | 79 | $1,373 |
| Pfizer | 50 | $768 |
| Novo Nordisk | 37 | $576 |
| GSK | 39 | $565 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $307 |
| Exact Sciences | 12 | $249 |
| Lilly USA, LLC | 15 | $244 |
| Amgen | 10 | $170 |
| UCB, Inc. | 9 | $146 |
| Novartis | 9 | $138 |
| Eisai Inc. | 8 | $138 |
| Merck | 8 | $137 |
| Amarin Pharma, Inc. | 7 | $100 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $87 |
| Johnson & Johnson | 5 | $79 |
| Ironwood Pharmaceuticals, Inc | 4 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Sanofi-aventis U.S. LLC | 4 | $59 |
| Nestle Healthcare Nutrition Inc. | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Dexcom, Inc. | 3 | $41 |
| Genentech USA, Inc. | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Bausch Health US, LLC | 2 | $29 |
| Tolmar, Inc. | 1 | $27 |
| Antares Pharma, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Lundbeck LLC | 1 | $23 |
| Biogen | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| SK Life Science, Inc. | 1 | $13 |
| Dermira, Inc. | 1 | $12 |
How this compares
$7,157 in reported general payments places this provider in the 95th percentile of 618 family practice providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $63,119 |
| OzempicSemaglutide | 65 | $62,136 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $42,166 |
| JanuviaSitagliptin Phosphate | 46 | $39,229 |
| JardianceEmpagliflozin | 31 | $30,759 |
| FarxigaDapagliflozin Propanediol | 20 | $19,277 |
| LinzessLinaclotide | 25 | $15,624 |
| TrulicityDulaglutide | 16 | $15,077 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,713 |
| EntrestoSacubitril/Valsartan | 14 | $12,827 |
| BrilintaTicagrelor | 17 | $12,393 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $4,270 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,105 |
| Atorvastatin Calcium | 315 | $3,764 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $2,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $768 | $63,119115 claims |
| Novo NordiskOzempic | $576 | $62,13665 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $565 | $46,27176 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,373 | $45,38359 claims |
| MerckJanuvia | $137 | $39,22946 claims |
| AbbVieLinzess | $1,377 | $15,62425 claims |
| Lilly USA, LLCTrulicity | $244 | $15,07716 claims |
| NovartisEntresto | $138 | $12,82714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 family practice providers in Michigan.
Other family practice in Taylor
- Amanda RoathLansing$1K
- Tara EliaBloomfield Township$738
- Sameer NaikPontiac$398
- Mark CecilioMarquette$214
- Esther LatourBattle Creek$124
- Manuj RattanCanton$20
- Jeffrey SweersMarquette$12
- Matthew AjluniAnn Arbor$0
- Becky PurkapleByron Center$0
- Arti BajpaiBruce$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.